{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:42:35Z","timestamp":1789926155577,"version":"4.0.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>The main goals of the pharmacological treatment of Heart failure with reduced ejection fraction (HFrEF) are the reduction of mortality and the prevention of hospitalizations. However, other outcomes such as improvements in cardiac remodeling and clinical status, functional capacity and quality of life, should be taken into account. Also, given the significant inter-individual and intra-individual variability of HF, and the fact that patients usually present with comorbidities, an appropriate treatment for HFrEF should exert a clinical benefit in most patient profiles irrespective of their characteristics or the presence of comorbidities, while providing organ protection beyond the cardiovascular system. The aim of this narrative review is to determine which are the proven effects of the guideline-directed treatments for HFrEF on five key clinical outcomes: cardiovascular mortality and hospitalization due to HF, sudden death, reverse cardiac remodeling, renal protection and evidence in hospitalized patients. Publications that fulfilled the pre-established selection criteria were selected and reviewed. Renin-angiotensin system (RAS) inhibitors, namely angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitors (ARNI), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), sodium-glucose co-transporter 2 inhibitors (SGLT2i) show a benefit in terms of mortality and hospitalization rates. ARNI, BB, and MRA have demonstrated a significant positive effect on the incidence of sudden death. ARB, ARNI, BB and SGLT2i have been associated with clear benefits in reverse cardiac remodeling. Additionally, there is consistent evidence of renal protection from ARB, ARNI, and SGLT2i in renal protection and of benefits for hospitalized patients from ARNI and SGLT2i. In conclusion, the combination of drugs that gather most beneficial effects in HFrEF, beyond cardiovascular mortality and hospitalization, would be ideally pursued.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1439696","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T04:28:00Z","timestamp":1725596880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review"],"prefix":"10.3389","volume":"11","author":[{"given":"Domingo","family":"Pascual-Figal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. Reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00392-014-0788-x","article-title":"Sex differences in new-onset heart failure","volume":"104","author":"Meyer","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijcard.2017.03.032","article-title":"Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure","volume":"240","author":"Pascual-Figal","year":"2017","journal-title":"Int J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jacc.2009.08.019","article-title":"Hospitalizations after heart failure diagnosis a community perspective","volume":"54","author":"Dunlay","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.rec.2018.08.014","article-title":"Population-based study of first hospitalizations for heart failure and the interaction between readmissions and survival","volume":"72","author":"Fern\u00e1ndez-Gass\u00f3","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1186\/s12913-020-05828-9","article-title":"Costs and healthcare utilisation of patients with heart failure in Spain","volume":"20","author":"Escobar","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e3319","DOI":"10.1002\/dmrr.3319","article-title":"Diabetes is a risk factor for the progression and prognosis of COVID-19","volume":"36","author":"Guo","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/ejhf.516","article-title":"Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency","volume":"18","author":"Anker","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/ejhf.880","article-title":"Acute heart failure and biomarkers: time also matters, don't relax","volume":"19","author":"Pascual-Figal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/s0735-1097(03)00947-1","article-title":"Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure","volume":"42","author":"Braunstein","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","article-title":"Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction","volume":"271","author":"Streng","year":"2018","journal-title":"Int J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/ejhf.887","article-title":"Physicians\u2019 guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/nejm198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/nejm199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/circulationaha.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jchf.2020.05.012","article-title":"NT-proBNP Response to sacubitril\/valsartan in hospitalized heart failure patients with reduced ejection fraction: tRANSITION study","volume":"8","author":"Pascual-Figal","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/nejm199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/circulationaha.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/s0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the losartan heart failure survival study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1161\/01.CIR.0000144474.65922.AA","article-title":"Effect of candesartan on cause-specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program","volume":"110","author":"Solomon","year":"2004","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1161\/circheartfailure.112.000003","article-title":"Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Bapoje","year":"2013","journal-title":"Circ Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.rec.2019.04.014","article-title":"Role of Beta-blockers in cardiovascular disease in 2019","volume":"72","author":"Mart\u00ednez-Milla","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1161\/01.cir.91.10.2573","article-title":"Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy","volume":"91","author":"Greenberg","year":"1995","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1023\/B:CARD.0000025756.32499.6f","article-title":"The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)","volume":"18","author":"Remme","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/s0735-1097(02)02063-6","article-title":"Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study","volume":"40","author":"Wong","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/01.cir.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0167-5273(02)00154-7","article-title":"Safety and efficacy of valsartan versus enalapril in heart failure patients","volume":"85","author":"Willenheimer","year":"2002","journal-title":"Int J Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0735-1097(97)00253-2","article-title":"Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The losartan pilot exercise study investigators","volume":"30","author":"Lang","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/hrt.2005.062463","article-title":"Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure","volume":"92","author":"Kasama","year":"2006","journal-title":"Heart"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"B45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/circulationaha.106.666016","article-title":"Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular remodeling with toprol-XL (REVERT) trial","volume":"116","author":"Colucci","year":"2007","journal-title":"Circulation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","article-title":"Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure","volume":"106","author":"Vizzardi","year":"2010","journal-title":"Am J Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/circheartfailure.109.906909","article-title":"Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","volume":"3","author":"Udelson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/dc19-2187","article-title":"Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial","volume":"43","author":"Singh","year":"2020","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/ejhf.2884","article-title":"Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: the DAPA-MODA study","volume":"25","author":"Pascual-Figal","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4070\/kcj.2011.41.2.61","article-title":"Effect of valsartan on N-terminal pro-brain natriuretic peptide in patient with stable chronic heart failure: comparison with enalapril","volume":"41","author":"Lee","year":"2011","journal-title":"Korean Circ J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B53","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/circulationaha.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"B57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory\u2014a position statement from the heart failure association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.amjmed.2011.10.013","article-title":"Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease","volume":"125","author":"Ahmed","year":"2012","journal-title":"Am J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jacc.2013.11.031","article-title":"Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data","volume":"63","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"B61","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","article-title":"Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial","volume":"11","author":"Cohen-Solal","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"B62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/eurjhf\/hfq038","article-title":"Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial","volume":"12","author":"Castagno","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"B63","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/circulationaha.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.amjcard.2011.02.322","article-title":"Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from get with the guidelines-heart failure)","volume":"107","author":"Krantz","year":"2011","journal-title":"Am J Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1161\/cir.0000000000000636","article-title":"Late-breaking science abstracts from the American Heart Association\u2019s scientific sessions 2018 and late-breaking abstracts in resuscitation science from the resuscitation science symposium 2018","volume":"138","year":"2018","journal-title":"Circulation"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jacc.2020.06.073","article-title":"Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin system antagonists","volume":"76","author":"Ambrosy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jchf.2015.03.008","article-title":"Effects of Beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis","volume":"3","author":"Prins","year":"2015","journal-title":"JACC Heart Fail"},{"key":"B69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1470320313482603","article-title":"Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure","volume":"16","author":"Rossi","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B70","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat","year":"2019","journal-title":"JACC Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1439696\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T09:30:42Z","timestamp":1727083842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1439696\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":71,"alternative-id":["10.3389\/fcvm.2024.1439696"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1439696","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"article-number":"1439696"}}